Compare INGN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | IMUX |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.5M | 200.4M |
| IPO Year | 2013 | 2013 |
| Metric | INGN | IMUX |
|---|---|---|
| Price | $6.78 | $15.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $11.25 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 310.3K | 219.1K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.42 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,668,000.00 | N/A |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.34 | $0.51 |
| 52 Week High | $9.13 | $15.77 |
| Indicator | INGN | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 66.87 |
| Support Level | $6.59 | $0.74 |
| Resistance Level | $7.12 | $15.77 |
| Average True Range (ATR) | 0.24 | 1.13 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 92.22 | 87.65 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.